Related Experiment Videos
Therapeutic options for Gram-positive infections
1Anti-infective Research Laboratory, Wayne State University and Detroit Receiving Hospital, Ml, USA. m.rybak@wayne.edu
The Journal of Hospital Infection
|April 3, 2002
Summary
Gram-positive infections are a global health burden. New antibiotics like linezolid are crucial for empirical treatment against resistant strains, improving patient outcomes.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Gram-positive infections present a significant global health challenge.
- Emerging resistant strains necessitate novel antimicrobial strategies.
- Standard treatments like oxacillin and vancomycin are becoming less effective.
Purpose of the Study:
- To evaluate the role of linezolid in empirical therapy for Gram-positive infections.
- To discuss the characteristics of linezolid relevant to clinical use.
- To highlight the need for new agents against multi-resistant Gram-positive pathogens.
Main Methods:
- Review of linezolid's spectrum of activity.
- Analysis of linezolid's pharmacodynamic profile.
- Assessment of linezolid's tolerability and efficacy.
Main Results:
- Linezolid demonstrates a valuable spectrum of activity against Gram-positive pathogens.
- Its pharmacodynamic profile and efficacy support its use in empirical therapy.
- Linezolid offers a viable option for initial treatment in at-risk patients.
Conclusions:
- Linezolid is an important agent for empirical treatment of Gram-positive infections.
- Its characteristics support its use in clinical practice.
- Ongoing development of agents like oritavancin, daptomycin, and glycylcyclines is critical for future challenges.